BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to SW620 cell line is 387
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DPP4 | 3009 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.0085 | 31285270 |
| EPCAM | 11529 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.211 | 31285270 |
| EPCAM | 11529 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by CFA and FACs | NA | 0.64 | 0.211 | 30115896 |
| EPCAM | 11529 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by FACs | NA | 0.64 | 0.211 | 26124007 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs and Western Blotting followed by IF staining and SFA | NA | 0.64 | 0.0753 | 31285270 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | IHC staining followed by SFA and qRT-PCR | NA | 0.64 | 0.0753 | 21412503 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by Western Blotting | NA | 0.64 | 0.0753 | 27894099 |
| LGR5 | 4504 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SP assay followed by SFA and Western Blotting | NA | 0.64 | 0.0753 | 28560069 |
| PROM1 | 9454 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.48 | 0.7582 | 22954703 |
| BMI1 | 1066 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.1135 | 28990068 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 1 | 28990068 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by Western Blotting | NA | 0.48 | 1 | 31139149 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by IF staining and SFA | NA | 0.48 | 1 | 31285270 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 27894099 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs | NA | 0.48 | 1 | 25154976 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs | NA | 0.48 | 1 | 25154976 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | 5-fluorouracil | FACs followed by SFA | NA | 0.48 | 1 | 27659530 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by SFA | NA | 0.48 | 1 | 29805588 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | MACs followed by SFA | NA | 0.48 | 1 | 31824193 |
| CD44 | 1681 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by CFA and FACs | NA | 0.48 | 1 | 30115896 |
| MACsC1 | 30215 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0042 | 28990068 |
| NANOG | 20857 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 30774996 |
| NANOG | 20857 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.5461 | 28990068 |
| NANOG | 20857 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.5461 | 33109220 |
| NANOG | 20857 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SP assay followed by SFA and Western Blotting | NA | 0.48 | 0.5461 | 28560069 |
| NANOG | 20857 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by CFA and qRT-PCR | NA | 0.48 | 0.5461 | 30115896 |
| NANOG | 20857 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qPCR | NA | 0.48 | 0.5461 | 31349708 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 30774996 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.6448 | 28990068 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.6448 | 33109220 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 35267511 |
| POU5F1 | 9221 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by CFA and qRT-PCR | NA | 0.48 | 0.6448 | 30115896 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.7582 | 28990068 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by Western Blotting | NA | 0.48 | 0.7582 | 31139149 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | MACs followed by SFA and Western Blotting | NA | 0.48 | 0.7582 | 27894099 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by Western Blotting and FACs | NA | 0.48 | 0.7582 | 26124007 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | MACs followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 0.7582 | 20587144 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | RT-PCR followed by FACs | NA | 0.48 | 0.7582 | 29899829 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | IHC staining followed by SFA | NA | 0.48 | 0.7582 | 21412503 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 33489876 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs | NA | 0.48 | 0.7582 | 21123622 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs | NA | 0.48 | 0.7582 | 25154976 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs | NA | 0.48 | 0.7582 | 32635858 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs and CFA | NA | 0.48 | 0.7582 | 25154976 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by CFA and Tumorigenicity assay | NA | 0.48 | 0.7582 | 23577199 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | 5-fluorouracil | FACs followed by SFA | NA | 0.48 | 0.7582 | 27659530 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 29805588 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by SFA | NA | 0.48 | 0.7582 | 31285270 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by Tumorigenicity assay and SFA | NA | 0.48 | 0.7582 | 22954703 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | MACs followed by SFA | NA | 0.48 | 0.7582 | 31824193 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by CFA and FACs | NA | 0.48 | 0.7582 | 30115896 |
| PROM1 | 9454 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SP assay followed by FACs | NA | 0.48 | 0.7582 | 21720213 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 30774996 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.5695 | 33109220 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 35267511 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by CFA and qRT-PCR | NA | 0.48 | 0.5695 | 30115896 |
| SOX2 | 11195 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qPCR | NA | 0.48 | 0.5695 | 31349708 |
| PRDX2 | 9353 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by Western Blotting and SFA | NA | 0.4 | 0.0074 | 27894099 |
| ALDH1A1 | 402 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.32 | 0.684 | 22954703 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qPCR and ALDEFLUOR assay | NA | 0.32 | 0.684 | 31349708 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by RT-PCR and ALDEFLUOR assay | NA | 0.32 | 0.684 | 30774996 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | 5-fluorouracil | FACs followed by SFA and ALDEFLUOR assay | NA | 0.32 | 0.684 | 27659530 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 33489876 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | ALDEFLUOR assay | NA | 0.32 | 0.684 | 19923910 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 29805588 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs | NA | 0.32 | 0.684 | 25154976 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs | NA | 0.32 | 0.684 | 32635858 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs and CFA | NA | 0.32 | 0.684 | 25154976 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by CFA and ALDEFLUOR assay | NA | 0.32 | 0.684 | 30115896 |
| ALDH1A1 | 402 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SP assay followed by ALDEFLUOR assay and Tumorigenicity assay | NA | 0.32 | 0.684 | 21720213 |
| CTNNB1 | 2514 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | MACs followed by RT-PCR and Tumorigenicity assay | NA | 0.32 | 0.0647 | 20587144 |
| CTNNB1 | 2514 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SP assay followed by SFA and Western Blotting | NA | 0.32 | 0.0647 | 28560069 |
| CTNNB1 | 2514 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qPCR | NA | 0.32 | 0.0647 | 31349708 |
| CXCR4 | 2561 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0498 | 27894099 |
| FURIN | 8568 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 35267511 |
| MIR195 | 31566 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qRT-PCR | Down | 0.2 | 0.0032 | 33109220 |
| MIR497 | 32088 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qRT-PCR | Down | 0.2 | 0.0053 | 33109220 |
| PCSK6 | 8569 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 35267511 |
| PCSK7 | 8748 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 35267511 |
| SLC7A11 | 11059 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 34385181 |
| CD24 | 1645 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.12 | 0.456 | 22954703 |
| CXCL1 | 4602 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.12 | 0.0064 | 22954703 |
| ABCG2 | 74 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by SFA | NA | 0.12 | 0.1739 | 29805588 |
| BMP2 | 1069 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA followed by FACs | NA | 0.12 | 0.0042 | 26124007 |
| CD24 | 1645 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by SFA | NA | 0.12 | 0.456 | 29805588 |
| CXCL1 | 4602 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | SFA and FACs followed by Migration assay | NA | 0.12 | 0.0064 | 30115896 |
| ITGA6 | 6142 | LTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs followed by SFA | NA | 0.12 | 0.0265 | 29805588 |
| A1CF | 24086 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 22954703 |
| ABCB1 | 40 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0604 | 22954703 |
| ABI2 | 24011 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ABRAXAS1 | 25829 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ACACA | 84 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ACSL3 | 3570 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| ACSL5 | 16526 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| ADA | 186 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| ADGRG6 | 13841 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| AGPS | 327 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| AKT1 | 391 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 22954703 |
| ALKBH2 | 32487 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| AOC1 | 80 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| APOBEC3G | 17357 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ARG2 | 664 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 22954703 |
| ARHGAP32 | 17399 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| ARHGDIB | 679 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| ARHGEF3 | 683 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| ARL4C | 698 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| ARRDC1 | 28633 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ARRDC3 | 29263 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| ASCC3 | 18697 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| ASCL2 | 739 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| ASMTL | 751 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ASNSD1 | 24910 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ATF1 | 783 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ATG10 | 20315 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| ATG16L1 | 21498 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ATXN1 | 10548 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 22954703 |
| BCHE | 983 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 22954703 |
| BCL11A | 13221 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| BPIFC | 16503 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| CA13 | 14914 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| CAMK2D | 1462 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| CAPRIN1 | 6743 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| CCDC22 | 28909 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| CCL20 | 10619 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 22954703 |
| CCN6 | 12771 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| CCNB1 | 1579 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| CD163 | 1631 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| CD302 | 30843 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| CD46 | 6953 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| CDADC1 | 20299 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| CDCA7 | 14628 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| CENPH | 17268 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| CENPK | 29479 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| CETN3 | 1868 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| CGNL1 | 25931 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| CHD1L | 1916 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| CHD9 | 25701 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| CHST3 | 1971 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| COBLL1 | 23571 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| COL18A1 | 2195 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| COL4A3BP | 2205 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| CRTAP | 2379 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| CSMD3 | 19291 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| CSRP2 | 2470 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| CSTA | 2481 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| CWC22 | 29322 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| CYCS | 19986 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 22954703 |
| CYP20A1 | 20576 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| CYP4V2 | 23198 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| CYTL1 | 24435 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| DCAF17 | 25784 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| DCPS | 29812 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| DDRGK1 | 16110 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| DHFR | 2861 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| DIAPH2-AS1 | 16972 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| DIS3L2 | 28648 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| DKK1 | 2891 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| DLX1 | 2914 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| DNAH1 | 2940 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| DNAJC10 | 24637 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| DNAJC21 | 27030 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| DOCK11 | 23483 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| DPEP1 | 3002 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| DYX1C1 | 21493 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| EEPD1 | 22223 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| ELOVL6 | 15829 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| EPHA4 | 3388 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| EPHX4 | 23758 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| EREG | 3443 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| ESF1 | 15898 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| FAM169A | 29138 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| FGF3 | 3681 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| FGF9 | 3687 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| FHOD3 | 26178 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| FKBP1A | 3711 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| FKBP7 | 3723 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| FOXL1 | 3817 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| FXYD2 | 4026 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| FZD5 | 4043 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| G0S2 | 30229 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 22954703 |
| GABARAPL1 | 4068 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 22954703 |
| GAD1 | 4092 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| GALNT3 | 4125 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| GBP3 | 4184 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| GCOM1 | 26424 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| GFM2 | 29682 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| GIGYF2 | 11960 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| GNAQ | 4390 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| GNE | 23657 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| GNG2 | 4404 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| GPD2 | 4456 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| GPRASP2 | 25169 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| GRB10 | 4564 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| GSN | 4620 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| GTF2H2 | 4656 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| GULP1 | 18649 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| GYG1 | 4699 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| HDAC4 | 14063 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| HELLS | 4861 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| HES6 | 18254 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| HIBCH | 4908 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| HMGCR | 5006 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| HNRNPA3 | 24941 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| HOMER1 | 17512 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| HOXA1 | 5099 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| HS2ST1 | 5193 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| HSD17B2 | 5211 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| IGFBP2 | 5471 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| IL15 | 5977 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| IL18 | 5986 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| IL6ST | 6021 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| ING1 | 6062 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ISM1 | 16213 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ITGB6 | 6161 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| ITPR2 | 6181 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| ITPRID2 | 11319 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| JAG1 | 6188 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0117 | 22954703 |
| JMJD4 | 25724 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| JMY | 28916 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| KLHL29 | 29404 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| KLK10 | 6358 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| KLRC3 | 6376 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| KRT16 | 6423 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 22954703 |
| KRT17 | 6427 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 22954703 |
| KRT23 | 6438 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 22954703 |
| L3MBTL3 | 23035 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| LAGE3 | 26058 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| LAMB1 | 6486 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| LAMB3 | 6490 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 22954703 |
| LANCL1 | 6508 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| LINS1 | 30922 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| LNPK | 21610 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| LPAR1 | 3166 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| LRP8 | 6700 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| LRRC34 | 28408 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| LRRC69 | 34303 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| LRRFIP1 | 6702 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| LY75 | 6729 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| MAD1L1 | 6762 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| MAP3K20 | 17797 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| MAP3K5 | 6857 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| MARS2 | 25133 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| MBD5 | 20444 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| MBOAT2 | 25193 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| MCPH1 | 6954 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| MDGA1 | 19267 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| MDM1 | 29917 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ME2 | 6984 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| METAP1D | 32583 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| METTL21A | 30476 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| MFF | 24858 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| MIS18A | 1286 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| MREG | 25478 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| MRPL44 | 16650 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| MRPS14 | 14049 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| MRPS27 | 14512 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| MSLN | 7371 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| MTERF4 | 28785 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| MUC13 | 7511 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| MUC13 | 7511 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 22954703 |
| MYEF2 | 17940 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| MYH4 | 7574 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| MYO1B | 7596 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| NBEAL1 | 20681 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| NDRG1 | 7679 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 22954703 |
| NF2 | 7773 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| NIN | 14906 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| NIPSNAP3A | 23619 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| NLN | 16058 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| NNMT | 7861 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| NR2F1 | 7975 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| NSMAF | 8017 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| NUDT13 | 18827 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| NUDT16L2P | 27189 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| NUDT7 | 8054 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| OBSL1 | 29092 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| OMA1 | 29661 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ORAI2 | 21667 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| ORC2L | 8488 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| OSBPL6 | 16388 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| OSGEPL1 | 23075 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| OSGIN2 | 1355 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| PANK2 | 15894 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| PARD6A | 15943 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 22954703 |
| PCSK5 | 8747 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| PCSK9 | 20001 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| PDE4D | 8783 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| PDK1 | 8809 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| PGM2 | 8906 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| PHACTR3 | 15833 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| PHOSPHO2 | 28316 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| PIK3AP1 | 30034 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| PLBD1 | 26215 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| PMS1 | 9121 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| POLK | 9183 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| POLR3G | 30075 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| PPAP2A | 9228 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| PRKRA | 9438 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| PRRX1 | 9142 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 22954703 |
| PRSS1 | 9475 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| PRSS2 | 9483 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| PRSS3P2 | 43788 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| PTK7 | 9618 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| PUS7L | 25276 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| QRICH2 | 25326 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| RAB3IP | 16508 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RABGAP1L | 24663 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RAD17 | 9807 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RALGAPA1 | 17770 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| RASGRF2 | 9876 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RBMS1 | 9907 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| RDH10 | 19975 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| RETREG2 | 28450 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RIF1 | 23207 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RIN2 | 18750 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RMND1 | 21176 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RPE | 10293 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RPS6KA2 | 10431 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| RQCD1 | 10445 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| RRP7A | 24286 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| RUNX2 | 10472 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| SCNN1A | 10599 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| SCRN3 | 30382 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SERF1A | 10755 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SERPINB5 | 8949 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 22954703 |
| SESN2 | 20746 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| SETBP1 | 15573 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| SFRP5 | 10779 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SGO2 | 30812 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| SGPP2 | 19953 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| SH3BGRL | 10823 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| SH3RF3 | 24699 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| SHROOM2 | 630 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SLC25A12 | 10982 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SLC38A10 | 28237 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| SLC38A6 | 19863 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| SLC39A10 | 20861 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SLC44A1 | 18798 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SLC5A3 | 11038 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| SMOC2 | 20323 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| SNAPC1 | 11134 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| SORBS2 | 24098 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| SP110 | 5401 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SPA17 | 11210 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| SPINK1 | 11244 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 22954703 |
| SQOR | 20390 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| SRPX | 11309 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| SSBP2 | 15831 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| STAM2 | 11358 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| STARD4 | 18058 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 22954703 |
| STK11 | 11389 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |
| STK25 | 11404 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| STK39 | 17717 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| STXBP6 | 19666 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SUMF1 | 20376 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| SUMO1 | 12502 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| TAF1B | 11533 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| TANC1 | 29364 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| TANK | 11562 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| TCF15 | 11627 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| TEAD2 | 11715 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| TFDP1 | 11749 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| TIGD1 | 14523 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| TLK1 | 11841 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| TMEM201 | 33719 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| TMSB15B | 28612 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| TNIK | 30765 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 22954703 |
| TNPO1 | 6401 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| TRAK2 | 13206 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| TRIM9 | 16288 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| TSLP | 30743 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| UBALD2 | 28438 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| URG4 | 30890 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| UTP15 | 25758 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| VEZT | 18258 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| VSNL1 | 12722 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| WDFY1 | 20451 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| WDR4 | 12756 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 22954703 |
| WDSUB1 | 26697 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| WNT10A | 13829 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| WNT11 | 12776 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| WT1 | 12796 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| XK | 12811 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| ZDHHC4 | 18471 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 22954703 |
| ZFYVE16 | 20756 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 22954703 |
| ZNF32 | 13095 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 22954703 |
| ZNF75A | 13146 | HTM | Dukes Type C Colon Cancer | Adenocarcinoma | SW620 | NA | FACs for CSC marker and CFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 22954703 |